FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2000406552> ?p ?o ?g. }

• W2000406552 endingPage "803" @default.
• W2000406552 startingPage "799" @default.
• W2000406552 abstract "Purpose To report our results with accelerated partial breast irradiation (APBI) in terms of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2/neu) status. Methods and Materials Between February 2003 and June 2009, 209 women with early-stage breast carcinomas were treated with APBI using multicatheter, MammoSite, or Contura brachytherapy to 34 Gy in 10 fractions twice daily over 5–7 days. Three patient groups were defined by receptor status: Group 1: ER or PR (+) and HER-2/neu (−) (n = 180), Group 2: ER and PR (−) and HER-2/neu (+) (n = 10), and Group 3: ER, PR, and HER-2/neu (−) (triple negative breast cancer, n = 19). Median follow-up was 22 months. Results Group 3 patients had significantly higher Scarff-Bloom-Richardson scores (p < 0.001). The 3-year ipsilateral breast tumor control rates for Groups 1, 2, and 3 were 99%, 100%, and 100%, respectively (p = 0.15). Group 3 patients tended to experience relapse in distant sites earlier than did non–Group 3 patients. The 3-year relapse-free survival rates for Groups 1, 2, and 3 were 100%, 100%, and 81%, respectively (p = 0.046). The 3-year cause-specific and overall survival rates for Groups 1, 2, and 3 were 100%, 100%, and 89%, respectively (p = 0.002). Conclusions Triple negative breast cancer patients typically have high-grade tumors with significantly worse relapse-free, cause-specific, and overall survival. Longer follow-up will help to determine whether these patients also have a higher risk of ipsilateral breast tumor relapse. To report our results with accelerated partial breast irradiation (APBI) in terms of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER-2/neu) status. Between February 2003 and June 2009, 209 women with early-stage breast carcinomas were treated with APBI using multicatheter, MammoSite, or Contura brachytherapy to 34 Gy in 10 fractions twice daily over 5–7 days. Three patient groups were defined by receptor status: Group 1: ER or PR (+) and HER-2/neu (−) (n = 180), Group 2: ER and PR (−) and HER-2/neu (+) (n = 10), and Group 3: ER, PR, and HER-2/neu (−) (triple negative breast cancer, n = 19). Median follow-up was 22 months. Group 3 patients had significantly higher Scarff-Bloom-Richardson scores (p < 0.001). The 3-year ipsilateral breast tumor control rates for Groups 1, 2, and 3 were 99%, 100%, and 100%, respectively (p = 0.15). Group 3 patients tended to experience relapse in distant sites earlier than did non–Group 3 patients. The 3-year relapse-free survival rates for Groups 1, 2, and 3 were 100%, 100%, and 81%, respectively (p = 0.046). The 3-year cause-specific and overall survival rates for Groups 1, 2, and 3 were 100%, 100%, and 89%, respectively (p = 0.002). Triple negative breast cancer patients typically have high-grade tumors with significantly worse relapse-free, cause-specific, and overall survival. Longer follow-up will help to determine whether these patients also have a higher risk of ipsilateral breast tumor relapse." @default.
• W2000406552 created "2016-06-24" @default.
• W2000406552 creator A5006577938 @default.
• W2000406552 creator A5011201812 @default.
• W2000406552 creator A5018762427 @default.
• W2000406552 creator A5022499471 @default.
• W2000406552 creator A5030798797 @default.
• W2000406552 creator A5033480832 @default.
• W2000406552 creator A5034985004 @default.
• W2000406552 creator A5048587038 @default.
• W2000406552 creator A5066313849 @default.
• W2000406552 creator A5075868505 @default.
• W2000406552 creator A5081317917 @default.
• W2000406552 creator A5087635493 @default.
• W2000406552 date "2010-11-01" @default.
• W2000406552 modified "2023-10-14" @default.
• W2000406552 title "Results With Accelerated Partial Breast Irradiation in Terms of Estrogen Receptor, Progesterone Receptor, and Human Growth Factor Receptor 2 Status" @default.
• W2000406552 cites W1748731440 @default.
• W2000406552 cites W1892496998 @default.
• W2000406552 cites W1947196376 @default.
• W2000406552 cites W1970975485 @default.
• W2000406552 cites W1981325985 @default.
• W2000406552 cites W1987395624 @default.
• W2000406552 cites W1988967981 @default.
• W2000406552 cites W1991953064 @default.
• W2000406552 cites W1995224853 @default.
• W2000406552 cites W2000685912 @default.
• W2000406552 cites W2012076348 @default.
• W2000406552 cites W2014610200 @default.
• W2000406552 cites W2027180980 @default.
• W2000406552 cites W2031535320 @default.
• W2000406552 cites W2038014393 @default.
• W2000406552 cites W2039680999 @default.
• W2000406552 cites W2040812935 @default.
• W2000406552 cites W2059243286 @default.
• W2000406552 cites W2060913005 @default.
• W2000406552 cites W2067420088 @default.
• W2000406552 cites W2072675161 @default.
• W2000406552 cites W2079442175 @default.
• W2000406552 cites W2082318061 @default.
• W2000406552 cites W2091600582 @default.
• W2000406552 cites W2102234892 @default.
• W2000406552 cites W2103740220 @default.
• W2000406552 cites W2104165093 @default.
• W2000406552 cites W2118605519 @default.
• W2000406552 cites W2119777918 @default.
• W2000406552 cites W2120491609 @default.
• W2000406552 cites W2122199930 @default.
• W2000406552 cites W2129472591 @default.
• W2000406552 cites W2132353145 @default.
• W2000406552 cites W2135979535 @default.
• W2000406552 cites W2138929540 @default.
• W2000406552 cites W2151255111 @default.
• W2000406552 cites W2157387547 @default.
• W2000406552 cites W2170602872 @default.
• W2000406552 doi "https://doi.org/10.1016/j.ijrobp.2009.08.081" @default.
• W2000406552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20869583" @default.
• W2000406552 hasPublicationYear "2010" @default.
• W2000406552 type Work @default.
• W2000406552 sameAs 2000406552 @default.
• W2000406552 citedByCount "19" @default.
• W2000406552 countsByYear W20004065522012 @default.
• W2000406552 countsByYear W20004065522013 @default.
• W2000406552 countsByYear W20004065522015 @default.
• W2000406552 countsByYear W20004065522016 @default.
• W2000406552 countsByYear W20004065522017 @default.
• W2000406552 countsByYear W20004065522022 @default.
• W2000406552 countsByYear W20004065522023 @default.
• W2000406552 crossrefType "journal-article" @default.
• W2000406552 hasAuthorship W2000406552A5006577938 @default.
• W2000406552 hasAuthorship W2000406552A5011201812 @default.
• W2000406552 hasAuthorship W2000406552A5018762427 @default.
• W2000406552 hasAuthorship W2000406552A5022499471 @default.
• W2000406552 hasAuthorship W2000406552A5030798797 @default.
• W2000406552 hasAuthorship W2000406552A5033480832 @default.
• W2000406552 hasAuthorship W2000406552A5034985004 @default.
• W2000406552 hasAuthorship W2000406552A5048587038 @default.
• W2000406552 hasAuthorship W2000406552A5066313849 @default.
• W2000406552 hasAuthorship W2000406552A5075868505 @default.
• W2000406552 hasAuthorship W2000406552A5081317917 @default.
• W2000406552 hasAuthorship W2000406552A5087635493 @default.
• W2000406552 hasConcept C121608353 @default.
• W2000406552 hasConcept C126322002 @default.
• W2000406552 hasConcept C126894567 @default.
• W2000406552 hasConcept C143998085 @default.
• W2000406552 hasConcept C170493617 @default.
• W2000406552 hasConcept C2777164284 @default.
• W2000406552 hasConcept C2780110267 @default.
• W2000406552 hasConcept C2908728163 @default.
• W2000406552 hasConcept C29456083 @default.
• W2000406552 hasConcept C530470458 @default.
• W2000406552 hasConcept C71924100 @default.
• W2000406552 hasConcept C84606932 @default.
• W2000406552 hasConcept C90924648 @default.
• W2000406552 hasConcept C98717036 @default.
• W2000406552 hasConceptScore W2000406552C121608353 @default.
• W2000406552 hasConceptScore W2000406552C126322002 @default.
• W2000406552 hasConceptScore W2000406552C126894567 @default.

• next